Want to see IN:AARTIPHARM full AI Analyst Report?
AARTIPHARM Stock Chart & Stats
₹842.40
₹9.55(1.45%)
At close: 4:00 PM EST
₹842.40
₹9.55(1.45%)
Day’s Range― - ―
52-Week Range₹583.85 - ₹946.45
Previous CloseN/A
Volume141.60K
Average Volume (3M)18.67K
Market Cap
₹60.57B
Enterprise Value₹81.13K
Total Cash (Recent Filing)₹96.16M
Total Debt (Recent Filing)₹7.54B
Price to Earnings (P/E)32.4
Beta0.88
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.6%
Share Statistics
EPS (TTM)20.57
Shares Outstanding90,679,810
10 Day Avg. Volume12,195
30 Day Avg. Volume18,670
Financial Highlights & Ratios
PEG Ratio-0.92
Price to Book (P/B)2.71
Price to Sales (P/S)3.16
P/FCF Ratio-30.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stable B2B API Manufacturing ModelAarti Pharmalabs’ core business is industrial-scale API and intermediate manufacture for pharmaceutical and chemical customers. This B2B, volume-driven model generates recurring contract demand, benefits from long sales cycles and technical barriers, and supports durable revenue visibility over months.
Historically Solid Profitability And MarginsSustained operating and net margins across FY2023–FY2025 indicate structural cost competitiveness and pricing power in core chemistries. Even with FY2026 pressure, historical margin strength shows the company can generate earnings from operations and absorb cyclical input cost swings over a multi-month horizon.
Positive Operating Cash Flow HistoryConsistently positive operating cash flow demonstrates the business can convert revenues into cash from core operations. This cash generation underpins working-capital needs and ongoing manufacturing investment, reducing reliance on short-term financing when operating performance is stable.
Bears Say
Rising LeverageA material uptick in borrowings in FY2026 weakens balance-sheet flexibility; higher leverage raises interest costs and reduces room to absorb shocks. If earnings stay pressured, elevated debt amplifies refinancing and covenant risk and constrains strategic investment over the coming months.
Negative And Inconsistent Free Cash FlowMeaningful negative free cash flow in recent years signals that capex or working-capital demands exceed operating cash generation. Persistent negative FCF increases dependence on external funding, heightens liquidity risk, and can limit the company's ability to reduce debt or invest in higher-margin capabilities.
Recent Revenue And Earnings DeclineA drop in revenue and a sharp fall in net income in FY2026 suggest demand or competitive pressures and reduce internal cash buffers. Continued earnings erosion would strain margins, impair debt service capacity, and make sustained recovery more difficult without structural changes in product mix or cost base.
Aarti Pharmalabs Limited News
AARTIPHARM FAQ
What was Aarti Pharmalabs Limited’s price range in the past 12 months?
Aarti Pharmalabs Limited lowest stock price was ₹583.85 and its highest was ₹946.45 in the past 12 months.
What is Aarti Pharmalabs Limited’s market cap?
Aarti Pharmalabs Limited’s market cap is ₹60.57B.
When is Aarti Pharmalabs Limited’s upcoming earnings report date?
Aarti Pharmalabs Limited’s upcoming earnings report date is Aug 07, 2026 which is today.
How were Aarti Pharmalabs Limited’s earnings last quarter?
Aarti Pharmalabs Limited released its earnings results on May 25, 2026. The company reported ₹6.74 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.74.
Is Aarti Pharmalabs Limited overvalued?
According to Wall Street analysts Aarti Pharmalabs Limited’s price is currently Overvalued.
Does Aarti Pharmalabs Limited pay dividends?
Aarti Pharmalabs Limited pays a Semiannually dividend of ₹1.5 which represents an annual dividend yield of 0.6%. See more information on Aarti Pharmalabs Limited dividends here
What is Aarti Pharmalabs Limited’s EPS estimate?
Aarti Pharmalabs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Pharmalabs Limited have?
Aarti Pharmalabs Limited has 90,679,810 shares outstanding.
What happened to Aarti Pharmalabs Limited’s price movement after its last earnings report?
Aarti Pharmalabs Limited reported an EPS of ₹6.74 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.666%.
Which hedge fund is a major shareholder of Aarti Pharmalabs Limited?
Currently, no hedge funds are holding shares in IN:AARTIPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
FDC Ltd.
―
Gufic Biosciences Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Orchid Pharma Limited
―